Biomarkers and Imaging Markers Screening for Intracerebral Hemorrhage Patients

What this Trial Is About

Intracerebral hemorrhage ICH is a serious type of stroke that causes high death rates and long-term disability. Researchers are investigating molecular and imaging markers to improve understanding of ICH diagnosis, treatment decisions, and prognosis. This observational study aims to find potential biomarkers from body samples and imaging scans to help with early warning, diagnosis, therapy monitoring, risk assessment, intervention, and outcome prediction in ICH patients. Participants include people diagnosed with spontaneous ICH confirmed by CT within 72 hours of symptom onset, along with healthy volunteers matched by age and sex. Samples such as blood, cerebral spinal fluid, urine, saliva, and possibly tissue will be collected. Imaging scans like CT, MRI, magnetic resonance spectroscopy MRS, and positron emission tomography PET will be performed repeatedly to detect imaging markers. During the study, researchers will collect body samples and conduct serial imaging scans to analyze biomarkers and imaging features within one month of onset. They will assess outcomes using scales like the Glasgow Outcome Scale Extended and modified Rankin scale at one year. The study includes monitoring brain imaging and clinical evaluations to better understand ICH progression and recovery over time.

Biomarkers and Imaging Markers for ICH